Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Key Points for Treatment of Advanced HNSCC

August 10th 2017

Next Steps in Research for Immunotherapy for HNSCC

August 10th 2017

Immunotherapy in the Peri-Operative Setting of HNSCC

August 10th 2017

Immunotherapy Combinations for HNSCC

August 10th 2017

Emerging Checkpoint Inhibitors for HNSCC

August 10th 2017

Take-Home Messages: Immunotherapy for HNSCC

August 10th 2017

Practical Issues Surrounding Immunotherapy for HNSCC

August 10th 2017

Pseudoprogression on Immunotherapy in HNSCC

August 10th 2017

Immunotherapy for HNSCC

August 10th 2017

New Therapies for HNSCC

August 10th 2017

Refining Chemoradiation for Advanced HNSCC

August 10th 2017

The Role of Induction Chemotherapy in HNSCC

August 10th 2017

Surgery for Locally Advanced HNSCC

August 10th 2017

De-Escalation of Therapy for HPV-Positive HNSCC

August 10th 2017

Personalized Approaches to Head and Neck Cancer Therapy

August 10th 2017

Head and Neck Cancer and the AJCC 8th Edition

August 10th 2017

Genetic Landscape of HNSCC

August 10th 2017

Biology of Head and Neck Cancer

August 10th 2017

Expert Weighs in on PARP Inhibitor Advances in Ovarian Cancer

August 8th 2017

Douglas Levine, MD, provides his insight on some of the recent data with PARP inhibitors in ovarian cancer, as well as his predictions for the field in the next several years.

Comprehensive Genomic Profiling May Identify Select Subsets in Ovarian Cancer

August 7th 2017

Julia A. Elvin, MD, PhD, discusses genomic research in ovarian cancer and how it could potentially impact treatment decisions for patients.